BostonGene’s Post

New article on our blog! This time, we share our insights about biomarkers in clinical trials. Learn from the basics: 🔹What are biomarkers? 🔹What are the methods to identify them? 🔹Why is their validation needed? 🔹How to use biomarkers in predicting or monitoring therapeutic responses? ...and much more. 📖 Read the full article: https://lnkd.in/dc-2P4K6 #ClinicalTrials #Biomarkers #MedicalResearch #PersonalisedMedicine #PrecisionMedicine #ClinicalTrials

Diagnosis for FMDs is challenging, and interest in establishing criteria for diagnostic efficiency is increasing. This systematic review breaks down biomarkers for FMDs, with functional myoclonus and tremor having the most validated biomarkers. https://loom.ly/uu_M3yY

Meet us today at hubXchange's Immuno-Oncology Xchange Boston 2024! Be sure to attend the roundtable discussion, "Multiomic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?" led by Michael Goldberg, PhD, VP, Research & Development at BostonGene. This session will explore using immune biomarkers to enhance drug development and patient outcomes. The focus will be on current applications, technological advancements, novel approaches and necessary validation and regulatory processes, highlighting how these strategies can improve therapeutic results and personalize treatments. https://lnkd.in/ej7CAYTT

#Researchers, with BI-3404 we share a well-characterized humanized antibody FLT3 agonist on #opnMe for a brief time. How would you propose to demonstrate a new role for FLT3 activation as a therapeutic concept in novel disease indications? Submit your innovative research ideas for a chance to access the molecule as well as funding. Learn more on #opnMe and get started https://lnkd.in/e2Rz7msw #OpenScience #Boehringer

Inoviv is excited to announce the launch of FibroKey™, a non-invasive, mass spectrometry-based multiplex assay designed to monitor fibrosis-related #biomarkers with precision. FibroKey™ delivers valuable insights into the progression of chronic kidney disease (#CKD) and other #fibrotic conditions, supporting therapeutic developers and #biopharma in advancing their drug development efforts. Learn more about how FibroKey™ can drive your #fibrosis research forward - https://lnkd.in/g8YB2zZp #FibrosisResearch #BiomarkerDiscovery #FibrosisTreatment #ChronicKidneyDisease #PharmaResearch #ClinicalResearch #BiotechInnovation #DrugDevelopment #Proteomics #FibrosisBiomarkers

#Researchers, with BI-3404 we share a well-characterized humanized antibody FLT3 agonist on #opnMe for a brief time. How would you propose to demonstrate a new role for FLT3 activation as a therapeutic concept in novel disease indications? Submit your innovative research ideas for a chance to access the molecule as well as funding. Learn more on #opnMe and get started https://lnkd.in/eUiWiJ5p #OpenScience #Boehringer

#Researchers, with BI-3404 we share a well-characterized humanized antibody FLT3 agonist on #opnMe for a brief time. How would you propose to demonstrate a new role for FLT3 activation as a therapeutic concept in novel disease indications?    Submit your innovative research ideas for a chance to access the molecule as well as funding. Learn more on #opnMe and get started:   https://lnkd.in/eBr_VAib #openscience #boehringer

#STORM is presenting 📢 interim Phase 1 data on its lead product, #STC15 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, entitled ‘𝙋𝘩𝙖𝙨𝙚 1 𝘿𝙤𝙨𝙚 𝙀𝙨𝙘𝙖𝙡𝙖𝙩𝙞𝙤𝙣 𝙖𝙣𝙙 𝘾𝙤𝘩𝙤𝙧𝙩 𝙀𝙭𝙥𝙖𝙣𝙨𝙞𝙤𝙣 𝙎𝙩𝙪𝙙𝙮 𝙀𝙫𝙖𝙡𝙪𝙖𝙩𝙞𝙣𝙜 𝙎𝙖𝙛𝙚𝙩𝙮, 𝙋𝙆, 𝙋𝘿 𝙖𝙣𝙙 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝘼𝙘𝙩𝙞𝙫𝙞𝙩𝙮 𝙤𝙛 𝙎𝙏𝘾-15, 𝙖 𝙈𝙀𝙏𝙏𝙇3 𝙄𝙣𝘩𝙞𝙗𝙞𝙩𝙤𝙧, 𝙞𝙣 𝙋𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙬𝙞𝙩𝘩 𝘼𝙙𝙫𝙖𝙣𝙘𝙚𝙙 𝙈𝙖𝙡𝙞𝙜𝙣𝙖𝙣𝙘𝙞𝙚𝙨 𝙬𝙤𝙧𝙡𝙙.’   The poster presentation will take place on June 1st from 9:00 - 12:00 CDT, and will focus on safety, pharmacokinetics, target modulation and clinical activity to support future clinical studies of STC-15.   𝙎𝙏𝘾-15 𝙞𝙨 𝙩𝘩𝙚 𝙛𝙞𝙧𝙨𝙩 𝙢𝙤𝙡𝙚𝙘𝙪𝙡𝙚 𝙨𝙥𝙚𝙘𝙞𝙛𝙞𝙘𝙖𝙡𝙡𝙮 𝙩𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜 𝙖𝙣 𝙍𝙉𝘼 𝙢𝙚𝙩𝘩𝙮𝙡𝙩𝙧𝙖𝙣𝙨𝙛𝙚𝙧𝙖𝙨𝙚 𝙚𝙣𝙯𝙮𝙢𝙚 𝙩𝙤 𝙚𝙣𝙩𝙚𝙧 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙙𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩!   The ASCO Annual Meeting is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.   Learn more about #STORM and its ongoing Phase 1 clinical trial in the press release linked in the comments below!   #ASCO2024 #lifesciences #biotech #drugdiscovery #research #METTL3 #METTL1 #RNA

Transform your research with the Q-Plex Mouse Cytokine Screen HS (15-Plex)! This ELISA-based assay measures 15 biomarkers using just 25 µL per well, with up to 80 samples in 5.5 hours. Reliable and cost-effective cytokine profiling. https://lnkd.in/ghuGXqmD

Several clinical trials support the use of Secretoneurin (SN) as a complementary biomarker to troponins, BNP and NT-proBNP which are currently the most frequently used biomarkers of heart failure development. #HeartMonth #HeartFailure